Medipharm Labs Corp (MEDIF)

$MEDIF this company has FDA approval?¿

$LABS.TSX $MEDIF 🔥 Without that proxy contest, we’d already be PROFITABLE this quarter! 💰📈 Over $2M spent… when one simple line could’ve done it: “We’re about to be profitable.” 😎 Next quarter? 🚀 It’s OUR time. Numbers. Don’t. Lie. #ProfitAhead #RocketMode #NumbersDontLie #InvestorEnergy

$MEDIF I wouldn't subscribe to this guy if my life depends on it. LOL

$LABS.TSX $MEDIF All those idiots who didn’t sell at 9 cents yesterday, you can buy back at 7 cents if you want, reverse split is imminent here

$MEDIF it's a shame they had to waste money on a proxy fight.

$MEDIF MediPharm Labs (TSX: LABS Revenue: $11.8M (+14% YoY) Gross Margin: 28% (↓ from 39% YoY) Adjusted EBITDA: –$0.6M Bull Case (Optimistic View) • Strong international momentum: 50% YoY growth in international medical cannabis; now more than half of total revenue. Expanding to high-value markets like Australia and the UK. • Clean balance sheet: Debt-free, $10.4M cash, $15M in owned assets • Shareholder support: Won proxy battle decisively (3:1 margin), providing governance stability • Year-to-date improvement: Adjusted EBITDA loss of $0.4M in 1H 2025 vs. $1.1M loss in 1H 2024 — trending toward break-even. Bear Case (Cautious View) • Margins under pressure: Gross margin fell to 28% from 39% • Still unprofitable: Negative Adjusted EBITDA this quarter (-$0.6M), worse than Q1 (+$0.14M). No proof yet of sustained profitability. • Non-operational cash boost: Cash increase largely from $4.5M asset sale — not from core business operations.

$MEDIF https://www.prnewswire.com/news-releases/medipharm-labs-positioned-for-unique-opportunities-on-possible-rescheduling-of-cannabis-in-the-united-states-302528922.html

$MEDIF thank the lucky stars you didn’t vote for Apollo scammers! They took all money out of check-cap and disappeared. 👻 zero votes zero credibility scum trash humans!

$LABS.TSX $MEDIF You could’ve sold when I alerted and bought back at .065 if you wanted, hit Follow and subscribe to get my alerts on time and make money

$MEDIF $LABS.TSX Apollo’s exit isn’t the end — it’s the cleanup 🧹. Heavy hands are dumping 💸. Focused eyes are loading 🎯📈. This isn’t hype — it’s accumulation 📊. Let them panic 😱. I see value 💎. I see potential 🚀.

$MEDIF MF!!!

$MEDIF $LABS.TSX 💚 We voted GREEN — now let’s see GREEN! 💸 We expect results — and we hope that little scare makes you work harder. 😏👀 #GreenProxy #InvestorMoves #ShowUsTheMoney #GreenDaysAhead #TimeToDeliver

$MEDIF $LABS.TSX 🚀 I Used to Be Team Green... Now I’m Seeing Gold 🚀 I supported MediPharm’s current management—I thought they were finally steadying the ship. But Apollo just came forward with something different. No hype. Just a bold, measurable plan: 🔸 $0.07 ➡️ Targeting $1+ in 3 years (that’s 10x+) 🔸 $0.25 per share in Year One 🔸 End golden parachutes & the asset fire-sale 🔸 Executive pay tied to performance—not upfront Let’s be real—we’re holding something with serious potential. That’s why there’s a fight over these cheap shares. It’s undervalued, and Apollo clearly knows it. This feels like more than just talk—it’s actual accountability and a strategy with teeth. 🗣 I’m curious what other real shareholders think. Are you leaning GOLD too? Or seeing it differently? #ShareholderVoices #MicrocapTurnaround #UndervaluedOpportunity

$MEDIF sounds better than the sh”@ show we have now

$MEDIF MediPharm Labs $LABS.TSX , $CHEK Check-Cap — diagnostics micro/nanocaps — no pstn, watching the Canadian-Israeli shitco drama 🍿 1- https://www.prnewswire.com/news-releases/apollo-technology-capital-corporation-poses-questions-that-medipharm-shareholders-should-ask-on-managements-conference-call-with-shareholders-302455297.html 2– https://www.globenewswire.com/news-release/2025/06/04/3093435/0/en/Check-Cap-claims-BMO-s-Chris-Taves-Illegally-Attacks-Israeli-NASDAQ-Listed-Company-During-Wartime.html

$CHEK $MEDIF Check-Cap 'publicly condemned' MediPharm Labs, Chairman Chris Taves The company said, "Check-Cap (CHEK) publicly condemned MediPharm Labs (MEDF)) and its Chairman, Chris Taves, Head of Asia for BMO Capital Markets, for disseminating derogatory, false, and misleading statements about Check-Cap during a profoundly sensitive and challenging time for Israeli Companies.Check-Cap is deeply disturbed that Mr. Taves would leverage the implied authority of his position as a senior BMO Executive to exploit the wartime circumstances currently affecting Israel, in order to knowingly spread false information aimed at harming Check-Cap's reputation, stock price, and business relationships. This conduct is not only unethical and unlawful - it is shameful. Specifically, MediPharm Labs's May 23, 2025 press release quoted Mr. Taves making what Check Cap believes to be demonstrably false statements about Check-Cap. Even more egregious, Mr. Taves, a financial executive who surely knows better, publicly disseminated his accusation of there being deficiencies in our public disclosures, without any actual factual basis whatsoever. Check-Cap believes that Mr. Taves is misusing his position of trust as a BMO Capital Markets Executive to intentionally issue these misleading statements during trading hours in order to manipulate and drive down Check-Cap's stock price, violating Section 9(a)(2) of the U.S. Securities Exchange Act of 1934. Check-Cap demands that MediPharm Labs and Mr. Taves immediately retract the defamatory press release, cease all related misleading communications, and publicly apologize for Mr. Taves disgraceful actions. The fact that Mr. Taves and MediPharm Labs have chosen to launch such deplorable and unfounded attacks on an Israeli company minutes before the start of Shabbat at a time of war is reprehensible. Check-Cap will vigorously defend its reputation and its rights against these highly unethical attempts at aspersion, market manipulation and interference in a public transaction."

$LABS.TSX $MEDIF Am I crazy for thinking profitability is just around the corner based on these numbers? Why isn’t management making more noise about this? 🤔 Given the current revenue growth, improving margins, and reduced operating costs, hitting profitability this year isn’t just wishful thinking — it’s a realistic expectation. 📈💰

$LABS.TSX $MEDIF 🔥Back in the day, talk was cheap, and respect had a price. You wanted a voice? You put your money down. Now everyone’s yapping, but real players know—only action moves the needle. 💰 🚀 Apollo’s playing the classic shakeout—rattle the weak hands, then load up while the sidelines second-guess. But when the latecomers come stampeding in—chasing what they once dismissed—it’ll be too late. ⏳ 🎯 This isn’t just a game. It’s the art of the move. 💥Game on

$LABS.TSX $MEDIF You could’ve sold when I alerted and bought back at .07 today if you wanted, hit Follow and subscribe to get my alerts on time and make money

$LABS.TSX $MEDIF You could’ve sold when I alerted and bought back at .075 today if you wanted, hit Follow and subscribe to get my alerts on time and make money

$LABS.TSX $MEDIF Told you to sell! Down to 8 cents now

$MEDIF It's clear that since David Pidduck took over as CEO in 2022, things have been improving at Medipharm Labs. Pharmaceuticals grade cannabis and synthetic THC (dronabinol). They also have industrial capacity Supercritical CO2 extraction which results in pharmaceutical grade cannabis products. Since Pidduck took over in 2022, the Key Performance Indicators are as clear as can be. Things are looking up for Medipharm Labs!